Scholarlink

Background <p>Patients with a body mass index (BMI) ≥ 50&#xa0;kg/m<sup>2</sup> present significant challenges in terms of treatment options, and data on long-term outcomes following metabolic and bariatric surgery (MBS) in this population remain limited. This study aims to explore the long-term outcomes of Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) in patients with BMI ≥ 50&#xa0;kg/m<sup>2</sup>, utilizing the Swiss-Finnish Bariatric Metabolic Outcome Score (SF-BARI Score)—a comprehensive tool that incorporates multiple outcome dimensions—and to identify factors that may influence these outcomes.</p> Methods <p>Retrospective cohort study of patients with BMI ≥ 50&#xa0;kg/m<sup>2</sup> submitted to RYGB or SG between January 2010 and September 2021, with more than 5&#xa0;years of follow-up. Several data were collected, and the SF-BARI score was calculated and analyzed. Statistical analysis was performed to identify variables that influenced the score.</p> Results <p>We identified 89 patients with long-term follow-up (mean 96.6&#xa0;months, SD 18.9) after RYGB or SG. The mean SF-BARI score was 94.2 (SD 29.5), with most patients’ outcomes categorized as good. Seventy-six (85.4%) patients had %TWL ≥ 20, but only 34.8% of patients had a final BMI &lt; 35&#xa0;kg/m<sup>2</sup>. Statistical analysis revealed that younger patients have higher SF-BARI scores related to comorbidities improvement.</p> Conclusion <p>Our findings suggest that both RYGB and SG lead to satisfactory long-term outcomes for treatment of patients with BMI ≥ 50&#xa0;kg/m<sup>2</sup>, according to the SF-BARI score. However, only one-third achieved a BMI &lt; 35&#xa0;kg/m<sup>2</sup>. Younger patients seem to achieve better results, particularly in comorbidity improvements. MBS outcomes should be reported in a standardized manner, addressing key components such as weight loss, improvement in comorbidities, complications, and quality of life.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

SF-BARI Score for Assessment of Long-Term Results in Patients with BMI ≥ 50 kg/m2 Submitted to Roux-en-Y Gastric Bypass or Sleeve Gastrectomy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月16日

查看全文
  • André Costa-Pinho,
  • João Araújo-Teixeira,
  • Sara Rodrigues,
  • Hugo Santos-Sousa,
  • Fernando Resende,
  • John Preto,
  • Eduardo Lima-da-Costa

摘要

Background

Patients with a body mass index (BMI) ≥ 50 kg/m2 present significant challenges in terms of treatment options, and data on long-term outcomes following metabolic and bariatric surgery (MBS) in this population remain limited. This study aims to explore the long-term outcomes of Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) in patients with BMI ≥ 50 kg/m2, utilizing the Swiss-Finnish Bariatric Metabolic Outcome Score (SF-BARI Score)—a comprehensive tool that incorporates multiple outcome dimensions—and to identify factors that may influence these outcomes.

Methods

Retrospective cohort study of patients with BMI ≥ 50 kg/m2 submitted to RYGB or SG between January 2010 and September 2021, with more than 5 years of follow-up. Several data were collected, and the SF-BARI score was calculated and analyzed. Statistical analysis was performed to identify variables that influenced the score.

Results

We identified 89 patients with long-term follow-up (mean 96.6 months, SD 18.9) after RYGB or SG. The mean SF-BARI score was 94.2 (SD 29.5), with most patients’ outcomes categorized as good. Seventy-six (85.4%) patients had %TWL ≥ 20, but only 34.8% of patients had a final BMI < 35 kg/m2. Statistical analysis revealed that younger patients have higher SF-BARI scores related to comorbidities improvement.

Conclusion

Our findings suggest that both RYGB and SG lead to satisfactory long-term outcomes for treatment of patients with BMI ≥ 50 kg/m2, according to the SF-BARI score. However, only one-third achieved a BMI < 35 kg/m2. Younger patients seem to achieve better results, particularly in comorbidity improvements. MBS outcomes should be reported in a standardized manner, addressing key components such as weight loss, improvement in comorbidities, complications, and quality of life.